Ipsen Dreams Of Capital Position In Oncology
Executive Summary
Ipsen's chief medical officer Sotirios Stergiopoulos talks about the company's R&D and licensing strategy that he hopes will push Ipsen's oncology unit to the next level.
You may also be interested in...
CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC
The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.